Cargando…

Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease

BACKGROUND: Oral corticosteroids were used to control stable chronic obstructive pulmonary disease (COPD) decades ago. However, recent guidelines do not recommend long-term oral corticosteroids (LTOC) use for stable COPD patients, partly because it causes side-effects such as respiratory muscle dete...

Descripción completa

Detalles Bibliográficos
Autores principales: Horita, Nobuyuki, Miyazawa, Naoki, Morita, Satoshi, Kojima, Ryota, Inoue, Miyo, Ishigatsubo, Yoshiaki, Kaneko, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976535/
https://www.ncbi.nlm.nih.gov/pubmed/24708443
http://dx.doi.org/10.1186/1465-9921-15-37
_version_ 1782310306598354944
author Horita, Nobuyuki
Miyazawa, Naoki
Morita, Satoshi
Kojima, Ryota
Inoue, Miyo
Ishigatsubo, Yoshiaki
Kaneko, Takeshi
author_facet Horita, Nobuyuki
Miyazawa, Naoki
Morita, Satoshi
Kojima, Ryota
Inoue, Miyo
Ishigatsubo, Yoshiaki
Kaneko, Takeshi
author_sort Horita, Nobuyuki
collection PubMed
description BACKGROUND: Oral corticosteroids were used to control stable chronic obstructive pulmonary disease (COPD) decades ago. However, recent guidelines do not recommend long-term oral corticosteroids (LTOC) use for stable COPD patients, partly because it causes side-effects such as respiratory muscle deterioration and immunosuppression. Nonetheless, the impact of LTOC on life prognosis for stable COPD patients has not been clarified. METHODS: We used the data of patients randomized to non-surgery treatment in the National Emphysema Treatment Trial. Severe and very severe stable COPD patients who were eligible for volume reduction surgery were recruited at 17 clinical centers in the United States and randomized during 1998-2002. Patients were followed-up for at least five years. Hazard ratios for death by LTOC were estimated by three models using Cox proportional hazard analysis and propensity score matching. RESULTS: The pre-matching cohort comprised 444 patients (prescription of LTOC: 23.0%. Age: 66.6 ± 5.4 year old. Female: 35.6%. Percent predicted forced expiratory volume in one second: 27.0 ± 7.1%. Mortality during follow-up: 67.1%). Hazard ratio using a multiple-variable Cox model in the pre-matching cohort was 1.54 (P = 0.001). Propensity score matching was conducted with 26 parameters (C-statics: 0.73). The propensity-matched cohort comprised of 65 LTOC(+) cases and 195 LTOC(−) cases (prescription of LTOC: 25.0%. Age: 66.5 ± 5.3 year old. Female: 35.4%. Percent predicted forced expiratory volume in one second: 26.1 ± 6.8%. Mortality during follow-up: 71.3%). No parameters differed between cohorts. The hazard ratio using a single-variable Cox model in the propensity-score-matched cohort was 1.50 (P = 0.013). The hazard ratio using a multiple-variable Cox model in the propensity-score-matched cohort was 1.73 (P = 0.001). CONCLUSIONS: LTOC may increase the mortality of stable severe and very severe COPD patients.
format Online
Article
Text
id pubmed-3976535
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39765352014-04-06 Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease Horita, Nobuyuki Miyazawa, Naoki Morita, Satoshi Kojima, Ryota Inoue, Miyo Ishigatsubo, Yoshiaki Kaneko, Takeshi Respir Res Research BACKGROUND: Oral corticosteroids were used to control stable chronic obstructive pulmonary disease (COPD) decades ago. However, recent guidelines do not recommend long-term oral corticosteroids (LTOC) use for stable COPD patients, partly because it causes side-effects such as respiratory muscle deterioration and immunosuppression. Nonetheless, the impact of LTOC on life prognosis for stable COPD patients has not been clarified. METHODS: We used the data of patients randomized to non-surgery treatment in the National Emphysema Treatment Trial. Severe and very severe stable COPD patients who were eligible for volume reduction surgery were recruited at 17 clinical centers in the United States and randomized during 1998-2002. Patients were followed-up for at least five years. Hazard ratios for death by LTOC were estimated by three models using Cox proportional hazard analysis and propensity score matching. RESULTS: The pre-matching cohort comprised 444 patients (prescription of LTOC: 23.0%. Age: 66.6 ± 5.4 year old. Female: 35.6%. Percent predicted forced expiratory volume in one second: 27.0 ± 7.1%. Mortality during follow-up: 67.1%). Hazard ratio using a multiple-variable Cox model in the pre-matching cohort was 1.54 (P = 0.001). Propensity score matching was conducted with 26 parameters (C-statics: 0.73). The propensity-matched cohort comprised of 65 LTOC(+) cases and 195 LTOC(−) cases (prescription of LTOC: 25.0%. Age: 66.5 ± 5.3 year old. Female: 35.4%. Percent predicted forced expiratory volume in one second: 26.1 ± 6.8%. Mortality during follow-up: 71.3%). No parameters differed between cohorts. The hazard ratio using a single-variable Cox model in the propensity-score-matched cohort was 1.50 (P = 0.013). The hazard ratio using a multiple-variable Cox model in the propensity-score-matched cohort was 1.73 (P = 0.001). CONCLUSIONS: LTOC may increase the mortality of stable severe and very severe COPD patients. BioMed Central 2014 2014-04-03 /pmc/articles/PMC3976535/ /pubmed/24708443 http://dx.doi.org/10.1186/1465-9921-15-37 Text en Copyright © 2014 Horita et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Horita, Nobuyuki
Miyazawa, Naoki
Morita, Satoshi
Kojima, Ryota
Inoue, Miyo
Ishigatsubo, Yoshiaki
Kaneko, Takeshi
Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease
title Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease
title_full Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease
title_fullStr Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease
title_full_unstemmed Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease
title_short Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease
title_sort evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976535/
https://www.ncbi.nlm.nih.gov/pubmed/24708443
http://dx.doi.org/10.1186/1465-9921-15-37
work_keys_str_mv AT horitanobuyuki evidencesuggestingthatoralcorticosteroidsincreasemortalityinstablechronicobstructivepulmonarydisease
AT miyazawanaoki evidencesuggestingthatoralcorticosteroidsincreasemortalityinstablechronicobstructivepulmonarydisease
AT moritasatoshi evidencesuggestingthatoralcorticosteroidsincreasemortalityinstablechronicobstructivepulmonarydisease
AT kojimaryota evidencesuggestingthatoralcorticosteroidsincreasemortalityinstablechronicobstructivepulmonarydisease
AT inouemiyo evidencesuggestingthatoralcorticosteroidsincreasemortalityinstablechronicobstructivepulmonarydisease
AT ishigatsuboyoshiaki evidencesuggestingthatoralcorticosteroidsincreasemortalityinstablechronicobstructivepulmonarydisease
AT kanekotakeshi evidencesuggestingthatoralcorticosteroidsincreasemortalityinstablechronicobstructivepulmonarydisease